PMID- 9263215
OWN - NLM
STAT- MEDLINE
DCOM- 19970929
LR  - 20190920
IS  - 0161-6412 (Print)
IS  - 0161-6412 (Linking)
VI  - 19
IP  - 4
DP  - 1997 Aug
TI  - Effect of tumor necrosis factor-alpha on the permeability of bovine brain 
      microvessel endothelial cell monolayers.
PG  - 369-76
AB  - The administration of chemotherapy to patients with tumors of the central nervous 
      system is often blocked by the blood-brain barrier. Tumor necrosis factor-alpha 
      (TNF-alpha) is a cytokine that promotes vascular permeability in addition to its 
      pro-inflammatory effects. However, no direct evidence exists as to whether 
      TNF-alpha may increase permeability of the BBB. We evaluated the effect of 
      TNF-alpha on the transport of cisplatin (CDDP) or high molecular weight dextran 
      labeled with fluorescein isothiocyanate (FITC-dextran) across bovine brain 
      microvessel endothelial cell (BMEC) monolayers that was conducted on side-by-side 
      diffusion chambers in vitro. The permeability coefficient for the transport of 
      CDDP across the untreated monolayer was 3.80 x 10(-5) cm sec-1 at 30 minutes. 
      After treating the BMEC monolayer with TNF-alpha (50 U ml-1 and 500 U ml-1) for 
      36 hours, the PC of CDDP increased significantly to 8.94 x 10(-5), and 14.43 x 
      10(-5) cm sec-1 respectively (p < 0.01). TNF-alpha had no effect on the transport 
      of FITC-dextran across the BMEC monolayers. Electron microscopy showed that the 
      tight junctions between the BMECs persisted even after treatment with TNF-alpha, 
      whereas they had been partially disrupted following exposure to mannitol, 1600 
      mOsm kg-1. TNF-alpha selectively promoted the in vitro permeability of the 
      blood-brain barrier to CDDP without disrupting tight junctions. This system could 
      be used as a model for experimental studies of chemotherapy. Findings suggested 
      that the combined administration of TNF-alpha and CDDP may be clinically useful.
FAU - Anda, T
AU  - Anda T
AD  - Department of Neurosurgery, Nagasaki University School of Medicine, Japan.
FAU - Yamashita, H
AU  - Yamashita H
FAU - Khalid, H
AU  - Khalid H
FAU - Tsutsumi, K
AU  - Tsutsumi K
FAU - Fujita, H
AU  - Fujita H
FAU - Tokunaga, Y
AU  - Tokunaga Y
FAU - Shibata, S
AU  - Shibata S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Dextrans)
RN  - 0 (Diuretics, Osmotic)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (fluorescein isothiocyanate dextran)
RN  - 3OWL53L36A (Mannitol)
RN  - I223NX31W9 (Fluorescein-5-isothiocyanate)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacokinetics
MH  - Blood-Brain Barrier/*drug effects
MH  - Brain/*blood supply
MH  - Cattle
MH  - Cells, Cultured
MH  - Cisplatin/*pharmacokinetics
MH  - Dextrans/pharmacokinetics
MH  - Diffusion Chambers, Culture
MH  - Diuretics, Osmotic/pharmacology
MH  - Endothelium, Vascular/cytology/drug effects/ultrastructure
MH  - Fluorescein-5-isothiocyanate/analogs & derivatives/pharmacokinetics
MH  - Mannitol/pharmacology
MH  - Microscopy, Electron
MH  - Tumor Necrosis Factor-alpha/*pharmacology
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - 10.1080/01616412.1997.11758599 [doi]
PST - ppublish
SO  - Neurol Res. 1997 Aug;19(4):369-76. doi: 10.1080/01616412.1997.11758599.